| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2724121 | The American Journal of Medicine | 2010 | 7 Pages |
Abstract
All-cause mortality was 10% lower in pooled analyses among older postmenopausal women receiving raloxifene 60 mg/day compared with placebo, due primarily to a reduction in noncardiovascular, noncancer deaths. The mechanism whereby raloxifene might reduce the risk of noncardiovascular death is unclear.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Deborah MD, MPH, Jane A. PhD, John L. MD, David A. PhD, Bruce H. MD, Jingli PhD, Steven R. MD,